Global Next Generation Cancer Diagnostics Market to Reach $57.8 Billion by 2030
The global market for Next Generation Cancer Diagnostics estimated at US$6.7 Billion in the year 2022, is projected to reach a revised size of US$57.8 Billion by 2030, growing at a CAGR of 31% over the analysis period 2022-2030. qPCR & Multiplexing, one of the segments analyzed in the report, is projected to record 33% CAGR and reach US$25.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Next Generation Sequencing segment is readjusted to a revised 26.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 30.1% CAGR
The Next Generation Cancer Diagnostics market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 30.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 27.9% and 26.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 21.5% CAGR.Select Competitors (Total 33 Featured) -
- Abbott
- Agilent Technologies
- Almac Group
- Cepheid
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Genomic Health
- Hologic
- Illumina
- Janssen Global Services
- Koninklijke Philips N.V
- Myriad Genetics
- Novartis AG
- Opko Health
- PerkinElmer
- Qiagen
- Sysmex Corporation
- Thermo Fisher Scientific
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Next Generation Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for qPCR & Multiplexing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for qPCR & Multiplexing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for LOAC & RT-PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for LOAC & RT-PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Biomarker Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Biomarker Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Proteomic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Proteomic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Genetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World 8-Year Perspective for Genetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 21: World Recent Past, Current & Future Analysis for Therapeutic Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 22: World 8-Year Perspective for Therapeutic Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World 8-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World 8-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 27: World Recent Past, Current & Future Analysis for Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 28: World 8-Year Perspective for Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 29: World Recent Past, Current & Future Analysis for Risk Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 30: World 8-Year Perspective for Risk Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 31: World Next Generation Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 32: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 34: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 35: USA 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 36: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 37: USA 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
CANADA
- Table 38: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 40: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 41: Canada 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 42: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 43: Canada 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
JAPAN
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 44: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 46: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 47: Japan 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 48: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 49: Japan 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
CHINA
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 50: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 52: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 53: China 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 54: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 55: China 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
EUROPE
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 56: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 57: Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- Table 58: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 59: Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 60: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 61: Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 62: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
FRANCE
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 64: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 65: France 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 66: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 67: France 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 68: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: France 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
GERMANY
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 70: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 71: Germany 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 72: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 73: Germany 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 74: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Germany 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
ITALY
- Table 76: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 77: Italy 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 78: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 79: Italy 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 80: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Italy 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
UNITED KINGDOM
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 82: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 83: UK 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 84: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 85: UK 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 86: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: UK 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
REST OF EUROPE
- Table 88: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 89: Rest of Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 90: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 91: Rest of Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
ASIA-PACIFIC
- Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 94: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 95: Asia-Pacific 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 96: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 97: Asia-Pacific 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
REST OF WORLD
- Table 100: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 101: Rest of World 8-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2023 & 2030
- Table 102: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 103: Rest of World 8-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2023 & 2030
- Table 104: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Rest of World 8-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Agilent Technologies
- Almac Group
- Cepheid
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Genomic Health
- Hologic
- Illumina
- Janssen Global Services
- Koninklijke Philips N.V
- Myriad Genetics
- Novartis AG
- Opko Health
- PerkinElmer
- Qiagen
- Sysmex Corporation
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 6.7 Billion |
| Forecasted Market Value ( USD | $ 57.8 Billion |
| Compound Annual Growth Rate | 30.9% |
| Regions Covered | Global |
